Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Expression and functional activity of breast cancer resistance protein (BCRP, ABCG2) transporter in the human choriocarcinoma cell line BeWo

Ceckova M, Libra A, Pavek P, Nachtigal P, Brabec M, Fuchs R, Staud F

Jazyk angličtina Země Austrálie

Perzistentní odkaz   https://www.medvik.cz/link/bmc07520309
E-zdroje Online

NLK Medline Complete (EBSCOhost) od 1998-01-01 do Před 1 rokem
Wiley Online Library (archiv) od 1997-01-01 do 2012-12-31

1. Breast cancer resistance protein (BCRP, ABCG2) is a drug efflux transporter that is believed to affect the drug disposition of several drugs and xenobiotics. In the present study, we evaluated the localization and functional expression of BCRP in the human choriocarcinoma cell line BeWo, an in vitro model of the human trophoblast, and compared it with the expression of P-glycoprotein (MDR1, ABCB1) as the most widely studied placental transporter. In addition, the expression of BCRP at the mRNA level was compared with that of MDR1 in the human term placenta. 2. Western blotting analysis revealed high endogenous expression of BCRP protein in BeWo cells. Using indirect immunofluorescence microscopy, we found that the BCRP transporter appears to be localized predominantly at the apical plasma membrane. Functional studies showed a significant effect of the BCRP inhibitors GF120918 (5 micromol/L) and Ko143 (1 micromol/L) on mitoxantrone accumulation and, thus, confirmed efflux activity of BCRP in BeWo cells. 3. Using absolute mRNA quantification with real-time reverse transcription-polymerase chain reaction, we found high expression of BCRP in BeWo cells, whereas no transcript of MDR1 (P-glycoprotein), the most extensively studied drug transporter, was detected. 4. In the human placenta, BCRP was localized predominantly in the syncytiotrophoblast layer; however, immunopositivity for the BXP-21 antibody was also observed in fetal vessels of the chorionic villi. The number of BCRP transcripts in the human term placenta was found to be more than 10-fold higher compared with the expression of MDR1. 5. In conclusion, we suggest that BeWo cells could serve as a suitable in vitro model to study trans-trophoblast transport of BCRP substrates and that placental BCRP can play an important role in preventing the accumulation of potentially toxic xenobiotics in the trophoblast cells.

000      
00000naa 2200000 a 4500
001      
bmc07520309
003      
CZ-PrNML
005      
20111210131055.0
008      
090331s2006 at e eng||
009      
AR
040    __
$a ABA008 $b cze $c ABA008 $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a at
100    1_
$a Čečková, Martina $7 xx0049092
245    10
$a Expression and functional activity of breast cancer resistance protein (BCRP, ABCG2) transporter in the human choriocarcinoma cell line BeWo / $c Ceckova M, Libra A, Pavek P, Nachtigal P, Brabec M, Fuchs R, Staud F
314    __
$a Department of Pharmacology and Toxicology, Faculty of Pharmacy in Hradec Kralove, Charles University in Prague, Heyrovskeho 1203, CZ-50005 Hradec Kralove, Czech Republic
520    9_
$a 1. Breast cancer resistance protein (BCRP, ABCG2) is a drug efflux transporter that is believed to affect the drug disposition of several drugs and xenobiotics. In the present study, we evaluated the localization and functional expression of BCRP in the human choriocarcinoma cell line BeWo, an in vitro model of the human trophoblast, and compared it with the expression of P-glycoprotein (MDR1, ABCB1) as the most widely studied placental transporter. In addition, the expression of BCRP at the mRNA level was compared with that of MDR1 in the human term placenta. 2. Western blotting analysis revealed high endogenous expression of BCRP protein in BeWo cells. Using indirect immunofluorescence microscopy, we found that the BCRP transporter appears to be localized predominantly at the apical plasma membrane. Functional studies showed a significant effect of the BCRP inhibitors GF120918 (5 micromol/L) and Ko143 (1 micromol/L) on mitoxantrone accumulation and, thus, confirmed efflux activity of BCRP in BeWo cells. 3. Using absolute mRNA quantification with real-time reverse transcription-polymerase chain reaction, we found high expression of BCRP in BeWo cells, whereas no transcript of MDR1 (P-glycoprotein), the most extensively studied drug transporter, was detected. 4. In the human placenta, BCRP was localized predominantly in the syncytiotrophoblast layer; however, immunopositivity for the BXP-21 antibody was also observed in fetal vessels of the chorionic villi. The number of BCRP transcripts in the human term placenta was found to be more than 10-fold higher compared with the expression of MDR1. 5. In conclusion, we suggest that BeWo cells could serve as a suitable in vitro model to study trans-trophoblast transport of BCRP substrates and that placental BCRP can play an important role in preventing the accumulation of potentially toxic xenobiotics in the trophoblast cells.
650    _2
$a ABC transportéry $x antagonisté a inhibitory $x genetika $x metabolismus $7 D018528
650    _2
$a akridiny $x farmakologie $7 D000166
650    _2
$a zvířata $7 D000818
650    _2
$a biologický transport $x účinky léků $7 D001692
650    _2
$a western blotting $7 D015153
650    _2
$a buněčné linie $7 D002460
650    _2
$a nádorové buněčné linie $7 D045744
650    _2
$a buněčná membrána $x metabolismus $7 D002462
650    _2
$a choriokarcinom $x genetika $x metabolismus $x patologie $7 D002822
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a regulace genové exprese u nádorů $7 D015972
650    _2
$a lidé $7 D006801
650    _2
$a imunohistochemie $7 D007150
650    _2
$a indoly $x farmakologie $x chemie $7 D007211
650    _2
$a fluorescenční mikroskopie $7 D008856
650    _2
$a mitoxantron $x farmakokinetika $7 D008942
650    _2
$a nádorové proteiny $x antagonisté a inhibitory $x genetika $x metabolismus $7 D009363
650    _2
$a P-glykoprotein $x genetika $x metabolismus $7 D020168
650    _2
$a placenta $x metabolismus $7 D010920
650    _2
$a těhotenství $7 D011247
650    _2
$a messenger RNA $x genetika $x metabolismus $7 D012333
650    _2
$a polymerázová řetězová reakce s reverzní transkripcí $7 D020133
650    _2
$a tetrahydroisochinoliny $x farmakologie $7 D044005
650    _2
$a financování organizované $7 D005381
700    1_
$a Libra, Antonín. $7 _BN007788
700    1_
$a Pávek, Petr $7 xx0093070
700    1_
$a Nachtigal, Petr $7 uk2009304471
700    1_
$a Brabec, Marianne
700    1_
$a Fuchs, Renate
700    1_
$a Štaud, František, $d 1970- $7 stk2007393932
773    0_
$w MED00007158 $t Clinical and experimental pharmacology & physiology $g Roč. 33, č. 1-2 (2006), s. 58-65 $x 0305-1870
910    __
$a ABA008 $b x $y 9
990    __
$a 20090312170439 $b ABA008
991    __
$a 20090717082604 $b ABA008
999    __
$a ok $b bmc $g 638112 $s 490910
BAS    __
$a 3
BMC    __
$a 2006 $b 33 $c 1-2 $d 58-65 $i 0305-1870 $m Clinical and experimental pharmacology & physiology $x MED00007158
LZP    __
$a 2009-B1/vtme

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...